Cargando…

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonstrated that targeted therapies potentially negativel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R., Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J., Marshall, Michael J. E., Cox, Kerry L., Turaj, Anna H., Cragg, Mark S., Klein, Christian, Carter, Matthew J., Tannheimer, Stacey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AAI 2018
Materias:	Clinical and Human Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857647/ https://www.ncbi.nlm.nih.gov/pubmed/29453281 http://dx.doi.org/10.4049/jimmunol.1700323

Ejemplares similares

Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
por: Reddy, Venkat R, et al.
Publicado: (2021)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis
por: Carter, M J, et al.
Publicado: (2017)

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Obinutuzumab: B-cell depletion: case report
Publicado: (2021)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Obinutuzumab/rituximab: Decreased platelet count and chronic COVID-19 pneumonia: case report
Publicado: (2020)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
por: Kvacskay, Peter, et al.
Publicado: (2022)

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
por: Bacac, Marina, et al.
Publicado: (2016)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report
por: Lachowiez, Curtis, et al.
Publicado: (2017)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Again, No Evidence for or Against the Existence of Ego Depletion: Opinion on “A Multi-Site Preregistered Paradigmatic Test of the Ego Depletion Effect”
por: Englert, Chris, et al.
Publicado: (2021)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia
por: Primo, Daniel, et al.
Publicado: (2018)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m4ddmmp72dg8g13qe6f6m6iai3